Literature DB >> 27701763

Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids.

Dorian R A Swarts1,2, Martina Rudelius3,4, Sandra M H Claessen1, Jack P Cleutjens5, Stefan Seidl6, Marco Volante7, Frans C S Ramaekers1, Ernst J M Speel5.   

Abstract

AIMS: Currently pulmonary carcinoids are separated into typical and atypical based on mitotic count and presence of necrosis, according to the World Health Organization. At variance with gastroenteropancreatic neuroendocrine tumours, which are graded based on mitotic count and Ki-67 proliferative index, the use of Ki-67 for grading pulmonary carcinoids is still under debate. METHODS AND
RESULTS: In this study we evaluated the prognostic impact of Ki-67 assessment in a multicentre cohort of 201 carcinoids [147 typical carcinoids (TCs) and 54 atypical carcinoids (ACs)] using manual analysis (2000 cells counted) and digital image analysis (in-house Leica Qwin program; ≥4500 cells counted). The Ki-67 proliferative index was correlated with overall survival by means of univariate analysis and in comparison to clinical data by means of multivariable analysis. The Ki-67 index was significantly higher in ACs than in TCs for both counting methods (P ≤ 2.7e-5 ). In addition, using cut-offs of 2.5% and 4% (manual counting) or 1% and 5% (digital analysis), the highest differences in overall survival were observed (P ≤ 0.0067). Nevertheless, histopathological classification into TCs and ACs showed an equally strong association with disease outcome, although Ki-67 had some additive value within TCs. Ki-67 index was not an independent predictor of survival in multivariable analysis.
CONCLUSIONS: Our study demonstrates that, although Ki-67 is a strong prognostic factor for pulmonary carcinoids, its usefulness in addition to histopathology in prediction of prognosis is limited. None the less, it may have additional value, especially in cases that are difficult to classify, in combination with histopathology and other molecular markers.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  Ki-67 proliferative index; MIB-1; histopathology; prognosis; pulmonary carcinoids

Mesh:

Substances:

Year:  2016        PMID: 27701763     DOI: 10.1111/his.13096

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  8 in total

Review 1.  Classification of pulmonary neuroendocrine tumors: new insights.

Authors:  Giuseppe Pelosi; Angelica Sonzogni; Sergio Harari; Adriana Albini; Enrica Bresaola; Caterina Marchiò; Federica Massa; Luisella Righi; Gaia Gatti; Nikolaos Papanikolaou; Namrata Vijayvergia; Fiorella Calabrese; Mauro Papotti
Journal:  Transl Lung Cancer Res       Date:  2017-10

2.  Distinctive pathological and clinical features of lung carcinoids with high proliferation index.

Authors:  Caterina Marchiò; Gaia Gatti; Federica Massa; Luca Bertero; Pierluigi Filosso; Giuseppe Pelosi; Paola Cassoni; Marco Volante; Mauro Papotti
Journal:  Virchows Arch       Date:  2017-06-19       Impact factor: 4.064

3.  A liquid biopsy for bronchopulmonary/lung carcinoid diagnosis.

Authors:  Mark Kidd; Irvin M Modlin; Ignat Drozdov; Harry Aslanian; Lisa Bodei; Somer Matar; Kyung-Min Chung
Journal:  Oncotarget       Date:  2017-12-29

Review 4.  The Ki-67 antigen in the new 2021 World Health Organization classification of lung neuroendocrine neoplasms.

Authors:  Giuseppe Pelosi; William D Travis
Journal:  Pathologica       Date:  2021-10

Review 5.  Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring.

Authors:  Claudio Luchini; Liron Pantanowitz; Volkan Adsay; Sylvia L Asa; Pietro Antonini; Ilaria Girolami; Nicola Veronese; Alessia Nottegar; Sara Cingarlini; Luca Landoni; Lodewijk A Brosens; Anna V Verschuur; Paola Mattiolo; Antonio Pea; Andrea Mafficini; Michele Milella; Muhammad K Niazi; Metin N Gurcan; Albino Eccher; Ian A Cree; Aldo Scarpa
Journal:  Mod Pathol       Date:  2022-03-05       Impact factor: 8.209

6.  A Multimodal Biomarker Predicts Dissemination of Bronchial Carcinoid.

Authors:  Ellen M B P Reuling; Dwayne D Naves; Pim C Kortman; Mark A M Broeckaert; Peter W Plaisier; Chris Dickhoff; Johannes M A Daniels; Teodora Radonic
Journal:  Cancers (Basel)       Date:  2022-06-30       Impact factor: 6.575

Review 7.  Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid Tumors.

Authors:  Philip T Sobash; Asad Ullah; Nagla Abdel Karim
Journal:  Cancers (Basel)       Date:  2022-09-28       Impact factor: 6.575

8.  A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal.

Authors:  Guido Rindi; David S Klimstra; Behnoush Abedi-Ardekani; Sylvia L Asa; Frederik T Bosman; Elisabeth Brambilla; Klaus J Busam; Ronald R de Krijger; Manfred Dietel; Adel K El-Naggar; Lynnette Fernandez-Cuesta; Günter Klöppel; W Glenn McCluggage; Holger Moch; Hiroko Ohgaki; Emad A Rakha; Nicholas S Reed; Brian A Rous; Hironobu Sasano; Aldo Scarpa; Jean-Yves Scoazec; William D Travis; Giovanni Tallini; Jacqueline Trouillas; J Han van Krieken; Ian A Cree
Journal:  Mod Pathol       Date:  2018-08-23       Impact factor: 7.842

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.